Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004.
Quarterly payment of $0.42 per share is 5.0% increase over prior year
Four Directors Re-Elected at Annual Meeting of Stockholders
RPM International Inc. (NYSE:RPM) today announced at its
ALF Episodes Premiering on Maximum Effort Channel This Saturday Will Be Surrounded by Sponsored Content for Mint Mobile, Fubo, Hims, MNTN and Ring, Featuring ALF Himself
Maximum Effort Channel, a partnership